Assortative sexual mixing among heterosexuals in Australia: implications for herd protection in males from a female human papillomavirus vaccination program

Sexual Health ◽  
2016 ◽  
Vol 13 (4) ◽  
pp. 395 ◽  
Author(s):  
Eric P. F. Chow ◽  
Christopher K. Fairley
Keyword(s):  
Human Papillomavirus ◽  
Sexual Health ◽  
Health Centre ◽  
Vaccination Program ◽  
Country Of Birth ◽  
Heterosexual Couples ◽  
Human Papillomavirus Vaccination ◽  
Men And Women ◽  
Herd Protection

The aim was to investigate the assortative sexual mixing by country of birth among heterosexuals in Australia. An analysis of 1060 heterosexual couples who attended the Melbourne Sexual Health Centre between 2011 and 2014 was conducted. Of the 1060 couples, 27% (n = 281) were both Australian-born men and women, and 42% (n = 445) were both overseas-born. Of the 171 couples with women aged ≤21 years, 41% (n = 70) were both born in Australia and 33% (n = 56) were both born overseas. A strong assortative mixing pattern by country of birth was observed among all 1060 couples (r = 0.361; 95% CI: 0.320–0.403), and among 171 couples with women aged ≤21 years (r = 0.481; 95% CI: 0.379–0.584).

Association between sexual mixing and genital warts in heterosexual men in Australia: the herd protection from the female human papillomavirus vaccination program

Sexual Health ◽  
2016 ◽  
Vol 13 (5) ◽  
pp. 489 ◽  
Author(s):  
Eric P. F. Chow ◽  
Christopher K. Fairley
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Health Centre ◽  
Genital Warts ◽  
Vaccination Program ◽  
Heterosexual Men ◽  
Heterosexual Couples ◽  
Human Papillomavirus Vaccination ◽  
Female Partners ◽  
Herd Protection

Australian-born women aged ≤32 years were eligible for the free female human papillomavirus (HPV) vaccination program introduced in 2007. A total of 1165 heterosexual couples attending the Melbourne Sexual Health Centre between 2011 and 2014 were included in this analysis. Findings showed the odds of having penile warts was 0.52-fold lower among men who had a female partner aged ≤32 years compared with men who had a female partners aged >32 years. This suggests men would have received herd protection from their female partners and hence they are at lower risk of acquiring genital warts.

Prevalence of other sexually transmissible infections in patients with newly diagnosed anogenital warts in a sexual health clinic

Sexual Health ◽  
2010 ◽  
Vol 7 (1) ◽  
pp. 55 ◽  
Author(s):  
Elizabeth A. Sturgiss ◽  
Fengyi Jin ◽  
Sarah J. Martin ◽  
Andrew Grulich ◽  
Francis J. Bowden
Keyword(s):  
Human Papillomavirus ◽  
Sexual Health ◽  
Health Centre ◽  
Health Clinic ◽  
Newly Diagnosed ◽  
Anogenital Warts ◽  
Human Papillomavirus Vaccination ◽  
Anogenital Wart ◽  
Screening Programs ◽  
Sexually Transmissible Infections

Background: Anogenital warts are a common initial presentation to the Canberra Sexual Health Centre. It is anticipated that the introduction of human papillomavirus vaccination will reduce the incidence of anogenital warts. The present study determines the prevalence of other sexually transmissible infections in patients newly diagnosed with warts who may not have presented for screening without the impetus of a genital lump. Methods: The prevalence of other sexually transmissible infections in new patients presenting to the Canberra Sexual Health Centre diagnosed with anogenital warts was determined from a retrospective clinical audit from 2002 to 2007. Results: A total of 1015 new patients were diagnosed with anogenital warts. Of this total cohort, 53 (5.2%) were found to be co-infected with either chlamydia and/or gonorrhoea. Only 13.2% of co-infected patients reported symptoms other than genital lumps. Of co-infected patients 11.3% reported contact with a partner with chlamydia and/or gonorrhoea. Not all patients were screened for other sexually transmissible infections: 762 (75.1%) were screened for chlamydia and 576 (56.7%) were screened for gonorrhoea. Of those tested, 6.8% of men and 6.9% of women were positive for chlamydia highlighting the importance of offering full sexually transmissible infection screening in those newly diagnosed with anogenital warts. Chlamydia was more common in younger patients who reported a higher number of sexual partners. Conclusions: It is anticipated that human papillomavirus vaccination will lead to a decline in anogenital wart incidence as well as other human papillomavirus associated disease. Although one opportunity for testing for other sexually transmissible infections may be lost in this population, the decrease in anogenital warts will leave clinicians with more time to pursue other screening programs. Education and screening campaigns should continue to focus on the asymptomatic nature of the majority of sexually transmissible infections.

scholarly journals Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance

2017 ◽  
Vol 65 (5) ◽  
pp. 827-832 ◽  
Author(s):  
Alexis J Pillsbury ◽  
Helen E Quinn ◽  
TaNisha D Evans ◽  
Peter B McIntyre ◽  
Julia M L Brotherton
Keyword(s):  
Human Papillomavirus ◽  
Population Level ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
Herd Protection

Use of the Delphi sorting technique to establish a core sexual history

2006 ◽  
Vol 17 (3) ◽  
pp. 170-172 ◽  
Author(s):  
Robin Tideman ◽  
Marian Pitts ◽  
Christopher K Fairley
Keyword(s):  
New Zealand ◽  
Sexual Health ◽  
Delphi Technique ◽  
Health Centre ◽  
Sexual History ◽  
Men And Women ◽  
The Core ◽  
Current State ◽  
Sorting Technique ◽  
History Of

The objective of this study was to develop a core sexual history to be used as a supplementary tool to assist sexual health physicians assess new clients attending a sexual health centre. Eight experts in sexual health medicine employed the Delphi technique and sexual history items from a previous study to generate a core sexual history. The core history contained 15 questions for men and women, with three additional specific questions for men and five for women. The current state of the clients' sexual health was explored (rather than a client's history of sexual behaviour) and three months (compared with 12 months and lifetime) came out strongly as the preferred timeframe for asking clients' behavioural questions. This core history may be useful in many clinics in Australia and New Zealand as its development was based on expert clinical experience of respected authorities within the field of sexual health medicine.

scholarly journals School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas

2019 ◽  
Vol 8 ◽  
pp. 100189 ◽  
Author(s):  
Sapna Kaul ◽  
Thuy Quynh N. Do ◽  
Enshuo Hsu ◽  
Kathleen M. Schmeler ◽  
Jane R. Montealegre ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Vaccine Uptake ◽  
Vaccination Program ◽  
Underserved Area ◽  
Human Papillomavirus Vaccination ◽  
School Based

scholarly journals A human papillomavirus vaccination program for low-income postpartum women

2016 ◽  
Vol 215 (3) ◽  
pp. 318.e1-318.e9 ◽  
Author(s):  
Abbey B. Berenson ◽  
Mahbubur Rahman ◽  
Jacqueline M. Hirth ◽  
Richard E. Rupp ◽  
Kwabena O. Sarpong
Keyword(s):  
Human Papillomavirus ◽  
Low Income ◽  
Vaccination Program ◽  
Postpartum Women ◽  
Human Papillomavirus Vaccination

scholarly journals Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan

Sexual Health ◽  
2015 ◽  
Vol 12 (6) ◽  
pp. 520 ◽  
Author(s):  
Luke B. Connelly ◽  
Ha N. D. Le
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Screening Program ◽  
Vaccine Coverage ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
The Cost

Background Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.

Sign in / Sign up

Export Citation Format

Share Document